In a study conducted by Cheng et al. [99], COVID-19 patients with lymphocyte count below 800/μl were selected for recombinant granulocyte–macrophage colony-stimulating factor (GM-CSF) treatment. This evidence concerns the gene CSF2 and COVID-19.